L-arginine supplementation to mitigate cardiovascular effects of walking outside in the context of traffic-related air pollution in participants with elevated blood pressure: A randomized, double-blind, placebo-controlled trial

BackgroundThe role of clonidine in the management of opioid-dependent individuals undergoing gradual detoxification.MethodA double-blind placebo-controlled trial was conducted on 86 voluntary in-patients (59 male, 27 female) aged 18–47 years, at a specialist drug-dependence treatment unit. Patients entered the trial when on 40 mg of methadone daily or less, and were randomised to receive incremental doses of clonidine (increasing from 0.2 mg daily to 1.2 mg daily) during a 14-day period of gradual methadone detoxification and for four weeks thereafter. Blood pressure was monitored and severity of opioid abstinence was assessed by questionnaire and by clinical examination.ResultHalf the subjects were withdrawn or defaulted from the trial by the end of two weeks, those receiving clonidine earlier than those receiving dummy medication (9 of the former and only one of the latter because of systemic hypotension). Similar proportions of subjects completed detoxification in the two groups. In those who completed detoxification, clonidine did not significantly reduce either the symptoms or objective signs of opioid withdrawal.ConclusionsThese findings suggest that clonidine has no place as an adjunct to a programme of gradual opioid detoxification.

Download Full-text

Double-Blind Placebo-Controlled Trial of Terazosin Effect on Blood Pressure and Urinary Output of Dopamine in Hypertensive Patients

The Journal of Clinical Pharmacology ◽

10.1002/j.1552-4604.1992.tb03888.x ◽

1992 ◽

Vol 32 (9) ◽

pp. 816-821 ◽

Cited By ~ 3

Author(s):

E. Romero ◽

M. Angeli ◽

M. Velasco ◽

E. Azar ◽

O. Bueno ◽

...

Keyword(s):

Blood Pressure ◽

Controlled Trial ◽

Urinary Output ◽

Double Blind ◽

Hypertensive Patients ◽

Double Blind Placebo

Download Full-text

Reduction of blood pressure with calcium and potassium supplementation in children with sodium sensitivity?a two years randomized double blind placebo controlled trial

American Journal of Hypertension ◽

10.1016/j.amjhyper.2004.03.393 ◽

2004 ◽

Vol 17 (5) ◽

pp. S150

Author(s):

J MU

Keyword(s):

Blood Pressure ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Sodium Sensitivity ◽

Potassium Supplementation

Download Full-text

A Double-Blind Placebo-Controlled Trial of the Effects of Short-term Potassium Supplementation on Blood Pressure and Atrial Natriuretic Peptide in Normotensive Women

American Journal of Hypertension ◽

10.1093/ajh/4.3.206 ◽

1991 ◽

Vol 4 (3 Pt 1) ◽

pp. 206-213 ◽

Cited By ~ 6

Author(s):

A. Barden ◽

L. J. Beilin ◽

R. Vandongen ◽

I. B. Puddey

Keyword(s):

Blood Pressure ◽

Atrial Natriuretic Peptide ◽

Natriuretic Peptide ◽

Controlled Trial ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Potassium Supplementation ◽

Atrial Natriuretic

Download Full-text

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium risk hypertension: study protocol for a randomized double-blind controlled trial

10.21203/rs.3.rs-361628/v1 ◽

2021 ◽

Author(s):

xiaochen Yang ◽

Xingjiang Xiong ◽

Yun Zhang ◽

Yongmei Liu ◽

Hongzheng Li ◽

...

Keyword(s):

Blood Pressure ◽

Inflammatory Responses ◽

Controlled Trial ◽

Controlled Study ◽

Control Group ◽

Double Blind ◽

Double Blind Placebo ◽

Medium Risk ◽

Tcm Syndrome ◽

And Control

Abstract IntroductionHypertension is one of the most important risk factors for cardiovascular disease, and its treatment and control rates are still low worldwide. The most effective strategy is that patients with hypertension should be diagnosed and treated early. Preliminary studies showed that the Bushen Jiangya granule (BSJY) may suppress ventricular hypertrophy and inflammatory responses, lower blood pressure and protect the target organs of hypertension. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of BSJY in patients with low-to-medium risk hypertension.Methods and analysisThis trial is a one-center, randomized, double-blind, placebo-controlled study. A total of 260 participants will be randomized in a 1:1 ratio to an experiment group (BSJY plus amlodipine) and a control group (placebo plus amlodipine). The trial cycle will last 8 weeks. The primary outcome is blood pressure, which is reduced to a threshold set out in Guiding Principles for Clinical Research of New Chinese Medicines. The secondary outcomes include the change in 24-h average systolic and diastolic blood pressure, heart rate variability, pharmacogenomic Evaluation, improvement in TCM Syndrome, serum pro-inflammatory/anti-inflammatory cytokines, etc. between the two groups. Safety in medication will also be evaluated. All the data will be recorded in electronic case report forms and analyzed by SPSS V.22.0.Ethics and dissemination This study has been approved by Research Ethics Committee of Guang’anmen Hospital,China Academy of Chinese Medical Sciences in Beijing, China (No. 2019-186-KY-01). The participants are volunteers, understand the process of this trial and sign an informed consent. The results of this study will be disseminated to the public through peer-reviewed journals and academic conferences. DiscussionWe hypothesize that patients with low-to-medium risk hypertension will benefit from BSJY. If successful, this study will provide evidence-based recommendations for clinicians.

Download Full-text